[Fareon]
000%
Restoring brain function
through biophysics
[Press kit]

Media resources.

Everything a journalist needs to cover Fareon: company boilerplate, the facts at a glance, brand and product assets, and our published research.

Press inquiries: press@fareon.co

Fareon wordmarkLogos [Everything in one place]Full press kitBrowse assets Headshots
[Company boilerplate]

Fareon is pioneering a new class of biophysics therapies designed to noninvasively treat brain disorders through precisely calibrated electromagnetic fields. The company’s Fareon Restore platform delivers proprietary Microtesla Magnetic Therapy (MMT) in order to activate biological pathways associated with resolution of inflammation and oxidative stress, repair, and recovery in the brain. In clinical trials, MMT has been delivered through a lightweight Fareon Restore headset connected to a tabletop console.

Working alongside leading academic and clinical collaborators, Fareon combines biophysics, high-content imaging and AI to systematically map how physical fields influence biology, accelerating the discovery of therapeutic signals and their translation from cellular models to patients. A public benefit corporation, Fareon is developing therapies for clinical populations where existing treatment options remain limited. The company’s lead product is intended to be administered comfortably in an outpatient or home setting and has been well tolerated in clinical studies to date.

Learn more at fareon.co.

For use in coverage. Please reproduce verbatim where possible. MMT is an investigational device. It has not been cleared by the U.S. Food and Drug Administration, and is not available for sale. Safety and effectiveness findings of the first-in-human feasibility study (n=30) are to be established in larger controlled trials.

[Facts at a glance]
Company
Fareon, Inc. · Delaware PBC
Headquarters
San Francisco, CA
Stage
Clinical-stage biophysics
Lead technology
Microtesla Magnetic Therapy (MMT)
First indication
Long COVID cognitive impairment
Clinical data
First-in-human feasibility study completed (2025, Mount Sinai, n=30) and published (Brain Communications, 2026); multicenter study planned for early 2027
Regulatory
Investigational · not FDA-cleared
[Brand & product assets]

Logos, product images and headshots.

[Research]

Published research

[Brain Communications · 2026]

Microtesla magnetic therapy for cognitive impairment in long COVID: a randomized pilot study

Canori et al. · Peer-reviewed

[medRxiv · 2026]

Plasma Proteomics Identifies a Microtesla Magnetic Therapy Response Signature in Long COVID

Brady et al. · Preprint, currently under peer review

[iScience · 2026]

Transcranial microtesla magnetic fields suppress neuroinflammation and neuronal oxidative stress burden

Nguyen et al. · Peer-reviewed

[Media contact]

Talk to the press office.

For interview requests, embargoed briefings, data and imagery.

Media inquiries
press@fareon.co
Agency · Cuttlefish Communications
Shira Derasmo · Chrystal Loyer
Agency phone
+1-917-280-2497
Newsroom
Releases and coverage